Sees Q3 adjusted EBITDA $26M-$30M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYM:
- Symbiotic options imply 14.5% move in share price post-earnings
- Symbotic price target lowered to $29 from $37 at Citi
- Symbotic price target lowered to $18 from $25 at Goldman Sachs
- Symbiotic call volume above normal and directionally bullish
- Symbotic’s Expansion Stagnation and Legal Challenges Signal Potential Stock Decline